164 related articles for article (PubMed ID: 25665655)
1. Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist.
Boyce M; Thomsen L
Scand J Gastroenterol; 2015 May; 50(5):550-9. PubMed ID: 25665655
[TBL] [Abstract][Full Text] [Related]
2. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A.
Fossmark R; Sørdal Ø; Jianu CS; Qvigstad G; Nordrum IS; Boyce M; Waldum HL
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1067-75. PubMed ID: 23072686
[TBL] [Abstract][Full Text] [Related]
3. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
[TBL] [Abstract][Full Text] [Related]
4. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
Boyce M; Moore AR; Sagatun L; Parsons BN; Varro A; Campbell F; Fossmark R; Waldum HL; Pritchard DM
Br J Clin Pharmacol; 2017 Mar; 83(3):466-475. PubMed ID: 27704617
[TBL] [Abstract][Full Text] [Related]
5. Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.
Lloyd KA; Parsons BN; Burkitt MD; Moore AR; Papoutsopoulou S; Boyce M; Duckworth CA; Exarchou K; Howes N; Rainbow L; Fang Y; Oxvig C; Dodd S; Varro A; Hall N; Pritchard DM
Cell Mol Gastroenterol Hepatol; 2020; 10(1):113-132. PubMed ID: 32004755
[TBL] [Abstract][Full Text] [Related]
6. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.
Boyce M; Dowen S; Turnbull G; van den Berg F; Zhao CM; Chen D; Black J
Br J Clin Pharmacol; 2015 May; 79(5):744-55. PubMed ID: 25335860
[TBL] [Abstract][Full Text] [Related]
7. Randomised trial of the effect of a gastrin/CCK
Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
Eur J Clin Pharmacol; 2017 Feb; 73(2):129-139. PubMed ID: 27796466
[TBL] [Abstract][Full Text] [Related]
8. Commentary: a gastrin antagonist against carcinoids--implications for PPI-induced hypergastrinaemia.
McCarthy DM
Aliment Pharmacol Ther; 2013 Jan; 37(2):276-7. PubMed ID: 23252778
[No Abstract] [Full Text] [Related]
9. Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice.
Aasarød KM; Ramezanzadehkoldeh M; Shabestari M; Mosti MP; Stunes AK; Reseland JE; Beisvag V; Eriksen EF; Sandvik AK; Erben RG; Schüler C; Boyce M; Skallerud BH; Syversen U; Fossmark R
J Endocrinol; 2016 Aug; 230(2):251-62. PubMed ID: 27325243
[TBL] [Abstract][Full Text] [Related]
10. The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development.
Kidd M; Siddique ZL; Drozdov I; Gustafsson BI; Camp RL; Black JW; Boyce M; Modlin IM
Regul Pept; 2010 Jun; 162(1-3):52-60. PubMed ID: 20144901
[TBL] [Abstract][Full Text] [Related]
11. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.
Boyce M; Warrington S; Black J
Br J Clin Pharmacol; 2013 Nov; 76(5):689-98. PubMed ID: 23432534
[TBL] [Abstract][Full Text] [Related]
12. Gastric Carcinoids.
Grozinsky-Glasberg S; Alexandraki KI; Angelousi A; Chatzellis E; Sougioultzis S; Kaltsas G
Endocrinol Metab Clin North Am; 2018 Sep; 47(3):645-660. PubMed ID: 30098721
[TBL] [Abstract][Full Text] [Related]
13. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.
Boyce M; David O; Darwin K; Mitchell T; Johnston A; Warrington S
Aliment Pharmacol Ther; 2012 Jul; 36(2):181-9. PubMed ID: 22607579
[TBL] [Abstract][Full Text] [Related]
14. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?
McCarthy DM
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963924
[TBL] [Abstract][Full Text] [Related]
15. Deletion of
Sundaresan S; Kang AJ; Hayes MM; Choi EK; Merchant JL
Gut; 2017 Jun; 66(6):1012-1021. PubMed ID: 26860771
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation.
Kidd M; Modlin IM; Black JW; Boyce M; Culler M
Regul Pept; 2007 Oct; 143(1-3):109-17. PubMed ID: 17531331
[TBL] [Abstract][Full Text] [Related]
17. Potential clinical indications for a CCK
Boyce M; Lloyd KA; Pritchard DM
Curr Opin Pharmacol; 2016 Dec; 31():68-75. PubMed ID: 27710813
[TBL] [Abstract][Full Text] [Related]
18. The role of gastric resection in the management of multicentric argyrophil gastric carcinoids.
Wängberg B; Grimelius L; Granérus G; Conradi N; Jansson S; Ahlman H
Surgery; 1990 Nov; 108(5):851-7. PubMed ID: 2237765
[TBL] [Abstract][Full Text] [Related]
19. The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils.
Sørdal Ø; Waldum H; Nordrum IS; Boyce M; Bergh K; Munkvold B; Qvigstad G
Helicobacter; 2013 Dec; 18(6):397-405. PubMed ID: 23865485
[TBL] [Abstract][Full Text] [Related]
20. Relationship between pernicious anaemia and gastric neuroendocrine cell disorders.
Spoelstra-de Man AM; Wagenaar SS; van der Sluys Veer A; Brouwer CB
Neth J Med; 2000 Feb; 56(2):56-62. PubMed ID: 10710942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
